FY2025 Earnings Forecast for STOK Issued By Chardan Capital

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Chardan Capital issued their FY2025 earnings per share estimates for shares of Stoke Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst R. Li expects that the company will post earnings of ($1.75) per share for the year. Chardan Capital has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Several other analysts also recently commented on STOK. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and issued a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $24.67.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $7.21 on Thursday. The company’s 50-day moving average is $9.32 and its 200 day moving average is $11.19. Stoke Therapeutics has a one year low of $7.06 and a one year high of $17.58. The company has a market capitalization of $389.90 million, a price-to-earnings ratio of -3.43 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million.

Institutional Investors Weigh In On Stoke Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its stake in shares of Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock valued at $1,028,000 after purchasing an additional 1,330 shares during the last quarter. Graham Capital Management L.P. lifted its position in Stoke Therapeutics by 8.5% in the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock worth $206,000 after buying an additional 1,453 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in Stoke Therapeutics by 2.0% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock worth $1,021,000 after buying an additional 1,791 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Stoke Therapeutics by 6.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock worth $414,000 after buying an additional 2,215 shares during the period. Finally, Rhumbline Advisers increased its position in Stoke Therapeutics by 6.0% during the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after acquiring an additional 2,787 shares during the last quarter.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now directly owns 63,962 shares of the company’s stock, valued at $554,550.54. This represents a 5.72 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock valued at $143,332 in the last 90 days. Insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.